NSB 0.00% 3.9¢ neuroscientific biopharmaceuticals ltd

Ann: Successful completion of pivotal ocular safety study, page-20

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 125 Posts.
    lightbulb Created with Sketch. 228
    Hi @Wasabibarako - indeed Bobby is right. The Total Addressable Market (TAM) for NSB is through the roof - see NSBs investor presentation from 2019 - https://hotcopper.com.au/threads/ann-investor-presentation.4679407/
    https://hotcopper.com.au/data/attachments/3321/3321257-ef4b2a8c77713e7217cc608cf502bb1f.jpg
    Yes that is what Brian Leedman, now ex non-executive chairman, eluded to when he did the health kick podcast for stock head earlier this year [HealthKick Podcast: NSB brings new solutions to medicine’s most stubborn eye problems on Stock Head]. The appointment of Mr Rennie however indicates that the company may have bigger ambitions than that - I am not sure. The company Mr Rennie comes from has drugs going through Ph2 I believe

    GLTAH and I hope you join us @Wasabibarako
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.